Sequential versus concomitant therapy for eradication of Helicobacter Pylori in patients with perforated duodenal ulcer: A randomized trial

Saudi Journal of Gastroenterology

Volumn 22, Issue 4, 2016, Pages 309-315

  Das, Roby ^a   Sureshkumar, Sathasivam ^a   Sreenath, Gubbi S ^a   Kate, Vikram ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Antibiotic therapy; Helicobacter pylori eradication; patient compliance; peptic ulcer perforation

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; RABEPRAZOLE; TINIDAZOLE; UREASE; ANTIINFECTIVE AGENT;

ARTICLE; BLOATING; CONTROLLED STUDY; DIARRHEA; DISEASE ERADICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DUODENUM PERFORATION; DUODENUM ULCER; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GIEMSA STAIN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METALLIC TASTE; NAUSEA; PATIENT COMPLIANCE; PERFORATED DUODENAL ULCER; RANDOMIZED CONTROLLED TRIAL; RAPID UREASE TEST; RECURRENT PEPTIC ULCER; TREATMENT DURATION; VOMITING; ADULT; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; DUODENAL ULCER; DUODENOSCOPY; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PEPTIC ULCER PERFORATION; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; DISEASE ERADICATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DUODENAL ULCER; DUODENOSCOPY; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER PERFORATION; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84983756116     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.187605     Document Type: Article

References (31)

1. Kumar D, Sinha AN. Helicobacter pylori infection delays ulcer healing in patients operated on for perforated duodenal ulcer. Indian J Gastroenterol 2002; 21: 19-22
2. Mihmanli M, Isgor A, Kabukcuoglu F, Turkay B, Cikla B, Baykan A. The effect of H. pylori in perforation of duodenal ulcer. Hepatogastroenterology 1998; 45: 1610-2
3. Kate V, Ananthakrishnan N, Badrinath S. Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: Retrospective and prospective randomized controlled studies. Br J Surg 2001; 88: 1054-8
4. Gisbert JP, Pajares JM. Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatment. Helicobacter 2003; 8: 159-67
5. Bose AC, Kate V, Ananthakrishnan N, Parija SC. Helicobacter pylori eradication prevents recurrence after simple closure of perforated duodenal ulcer. J Gastroenterol Hepatol 2007; 22: 345-8
6. Malfertheiner P, Megraud F, OMorain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection - The Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-64
7. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial. Ann Intern Med 2007; 146: 556-63
8. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53
9. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587
10. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26
11. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: Systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-79
12. Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, et al. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: A randomized trial. J Clin Gastroenterol 2013; 47: 228-32
13. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41.e1
14. Prasad S, Mathan M, Chandy G, Rajan DP, Venkateswaran S, Ramakrishna BS, et al. Prevalence of Helicobacter pylori in Southern Indian controls and patients with gastroduodenal disease. J Gastroenterol Hepatol 1994; 9: 501-6
15. Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2013; 4: 23-7
16. Valooran GJ, Kate V, Jagdish S, Basu D. Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure. Scand J Gastroenterol 2011; 46: 1045-50
17. Javid G, Zargar SA, Bhat K, Khan BA, Yatoo GN, Gulzar GM, et al. Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: A randomized comparative trial. Indian J Gastroenterol 2013; 32: 190-4
18. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Duenas-Sadornil C, Hernandez-Alonso M, et al. Nonbismuth quadruple (concomitant) therapy: Empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter 2012; 17: 269-76
19. Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 2012; 17: 282-5
20. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34
21. McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63: 244-9
22. Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: A randomized pilot study. Helicobacter 2013; 18: 180-6
23. Abu-Safieh Y, Yamin H. Sequential and concomitant non-bismuth quadruple therapies are ineffective for H. pylori eradication in Palestine. A randomized trial. Open J Gastroenterol 2012; 2: 177-80
24. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: The global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514-33
25. Smith SM. An update on the treatment of Helicobacter pylori infection. EMJ Gastroenterol 2015; 4: 101-7
26. Coghlan JG, Gilligan D, Humphries H, McKenna D, Dooley C, Sweeney E, et al. Campylobacter pylori and recurrence of duodenal ulcers - A 12-month follow-up study. Lancet 1987; 2: 1109-11
27. Nanivadekar SA, Sawant PD, Patel HD, Shroff CP, Popat UR, Bhatt PP. Association of peptic ulcer with Helicobacter pylori and the recurrence rate. A three year follow-up study. J Assoc Physicians India 1990; 38 Suppl 1: 703-6
28. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: A prospective randomized study. J Med Microbiol 2014; 63(Pt 5): 748-52
29. Huang YK, Wu MC, Wang SS, Kuo CH, Lee YC, Chang LL, et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis 2012; 13: 232-8
30. Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, DAmbrosio P, Castorani L, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647-50
31. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial. Lancet 2011; 378: 507-14